Literature DB >> 11348709

Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains.

J A Tree1, C Richardson, A R Fooks, J C Clegg, D Looby.   

Abstract

Different types of microcarriers were assessed for the large-scale culture of influenza virus in the Madin-Darby canine kidney (MDCK) cells. Both porous and solid carriers were examined. A higher titre of influenza A/PR8/34 virus was recovered from cultures using solid (1.3x10(9) PFU per ml) rather than porous carriers (4.0x10(8) PFU per ml). High titres of virus (1.0x10(9) PFU per ml) were also obtained from roller bottle cultures of MDCK cells and the traditional culture technique using embryonated hens' eggs (3.9x10(9) PFU per ml). We found that solid carriers composed of dextran with a positive charge are the most suitable carriers for the large-scale growth of influenza A virus in MDCK cells using serum-free media.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11348709     DOI: 10.1016/s0264-410x(01)00053-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  30 in total

Review 1.  Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target.

Authors:  Neetu Singh; Aseem Pandey; Suresh K Mittal
Journal:  Expert Rev Mol Med       Date:  2010-04-29       Impact factor: 5.600

2.  Anoikis-resistant MDCK cells carrying susceptibilities to TNF-alpha and verotoxin that are suitable for influenza virus cultivation.

Authors:  Reiko Tsutsumi; Shigemi Fujisaki; Masanori Shozushima; Koichi Saito; Shigehiro Sato
Journal:  Cytotechnology       Date:  2006-11-30       Impact factor: 2.058

3.  Failure-to-thrive syndrome associated with tumor formation by Madin-Darby canine kidney cells in newborn nude mice.

Authors:  Lauren R Brinster; Romelda L Omeir; Gideon S Foseh; Juliete N Macauley; Philip J Snoy; Joel J Beren; Belete Teferedegne; Keith Peden; Andrew M Lewis
Journal:  Comp Med       Date:  2013-08       Impact factor: 0.982

Review 4.  Cell culture-based influenza vaccines: A necessary and indispensable investment for the future.

Authors:  Nagendra R Hegde
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  The Effects of Statistical Multiplicity of Infection on Virus Quantification and Infectivity Assays.

Authors:  Bhaven A Mistry; Maria R D'Orsogna; Tom Chou
Journal:  Biophys J       Date:  2018-06-19       Impact factor: 4.033

Review 6.  Advances in novel influenza vaccines: a patent review.

Authors:  Jae-Min Song
Journal:  J Microbiol       Date:  2016-05-27       Impact factor: 3.422

7.  Antimycotic-antibiotic amphotericin B promotes influenza virus replication in cell culture.

Authors:  Elisabeth Roethl; Manuela Gassner; Brigitte M Krenn; Ekaterina A Romanovskaya-Romanko; Helena Seper; Julia Romanova; Sabine Nakowitsch; Sanda Sturlan; Markus Wolschek; Alexej Sirotkin; Oleg Kiselev; Thomas Muster; Andrej Egorov
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

8.  Conversion of MDCK cell line to suspension culture by transfecting with human siat7e gene and its application for influenza virus production.

Authors:  Chia Chu; Vladimir Lugovtsev; Hana Golding; Michael Betenbaugh; Joseph Shiloach
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-17       Impact factor: 11.205

9.  Quantitation of influenza virus using field flow fractionation and multi-angle light scattering for quantifying influenza A particles.

Authors:  Tatiana Bousse; David A Shore; Cynthia S Goldsmith; M Jaber Hossain; Yunho Jang; Charles T Davis; Ruben O Donis; James Stevens
Journal:  J Virol Methods       Date:  2013-07-31       Impact factor: 2.014

10.  Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virus.

Authors:  Zuzana Biesova; Mark A Miller; Rachel Schneerson; Joseph Shiloach; Kim Y Green; John B Robbins; Jerry M Keith
Journal:  Vaccine       Date:  2009-08-15       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.